Apellis Pharmaceuticals, Inc. APLS NASDAQ

Apellis Pharmaceuticals, Inc. (APLS) reported total assets of $1.08B and total liabilities of $705.11M for fiscal year 2025, resulting in total equity of $370.15M.

The company held $467.76M in cash and short-term investments. Total debt stood at $486.31M, with net debt of $18.55M. The Debt-to-Equity (D/E) ratio was 1.31 (moderate).

Current ratio is 3.14, indicating strong short-term liquidity. Interest coverage is 1.3x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (65/100) — Total assets $1.08B and equity $370.15M support the company's competitive scale
• VALUE (18/100) — Debt-to-Equity 1.31 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 48/100 with 1/7 criteria passed.

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

RXDX

Prometheus Biosciences, Inc.

$199.92

+0.09%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

CERE

Cerevel Therapeutics Holdings, Inc.

$44.96

+0.74%

IMVT

Immunovant, Inc.

$26.55

+5.69%

TERN

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%

MRTX

Mirati Therapeutics, Inc.

$58.70

-0.17%